Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population ...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS ...

Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...

Now two KRAS inhibitors, Amgen’s sotorasib (Lumakras) and BMS/Mirati’s adagrasib (Krazati), are approved — and many more are in the clinic. But while clinicians had high hopes that these ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations. “The ...

In 2021, the first KRAS inhibitor was approved to treat non-small cell lung cancer with KRAS G12C mutations, but with longer follow-up, it has become clear that KRAS-mutant cancers can quickly ...